Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer
| Autor: | Ariadna Juarez Garcia, John R. Penrod, Trong Kim Le, Florence Wilson, Pranav Abraham, D. Ross Camidge, Keith Chan, Jeroen P. Jansen, Beata Korytowsky, Shannon Cope, Sam Keeping, Yong Yuan, T. Gu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Comparative Effectiveness Research medicine.medical_specialty Lung Neoplasms Standard of care medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans 030212 general & internal medicine Lung cancer Proportional Hazards Models Chemotherapy business.industry Health Policy Hazard ratio Standard of Care medicine.disease Doubly robust Survival Rate Nivolumab Treatment Outcome Third line 030220 oncology & carcinogenesis Non small cell business |
| Zdroj: | Journal of Comparative Effectiveness Research. 9:1275-1284 |
| ISSN: | 2042-6313 2042-6305 |
| DOI: | 10.2217/cer-2020-0134 |
| Popis: | Aim: To estimate the comparative effectiveness of nivolumab versus standard of care (SOC) in terms of overall survival (OS) for small-cell lung cancer patients treated with two prior lines of chemotherapy, in other words, third line in the USA. Materials & methods: Data were from CheckMate 032, a single-arm trial of nivolumab, and real-world electronic patient records. Comparisons of OS were conducted using three different methods to adjust for differences (regression, weighting and doubly robust) between the populations. Results: Nivolumab was associated with longer survival compared with SOC (hazard ratio for OS: 0.58–0.70) across all methods for adjustment. Conclusion: Nivolumab was more efficacious in terms of OS as third-line treatment for small-cell lung cancer compared with current SOC in the USA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|